Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Jingwen Wang, Lugui Qiu et al.|Journal of Hematology & Oncology|2017Cited by 256
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Zengjun Li et al.|The Lancet Oncology|2023Cited by 55